**Name of Journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 20262**

**Manuscript Type: Original Article**

***Retrospective Study***

**Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development**

Shakado S *et al*.AFP and DCP predict HCC development

**Satoshi Shakado, Shotaro Sakisaka, Kazuaki Chayama, Takeshi Okanoue, Joji Toyoda, Namiki Izumi, Akihiro Matsumoto, Tetsuo Takehara, Akio Ido, Yoichi Hiasa, Kentaro Yoshioka, Hideyuki Nomura, Yoshiyuki Ueno, Masataka Seike, Hiromitsu Kumada**

**Satoshi Shakado, Shotaro Sakisaka**, Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Fukuoka City, Fukuoka 814-0180, Japan

**Kazuaki Chayama,** Department of Gastroenterology and Metabolism, Applied Life Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima City, Hiroshima 734-8553, Japan

**Takeshi Okanoue,** Center of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Suita City, Osaka 564-0013, Japan

**Joji Toyoda,** Department of Gastroenterology and Hepatology, Sapporo Kousei Hospital, Sapporo City, Hokkaido 060-0033, Japan

**Namiki Izumi,** Department of Gastroenterology and Hepatology, Musashino Red-Cross Hospital, Musashino City, Tokyo 180-8610, Japan

**Akihiro Matsumoto,** Department of Medicine, Shinshu University School of Medicine, Matsumoto City, Nagano 390-8621, Japan

**Tetsuo Takehara,** Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita City, Osaka 565-0871, Japan

**Akio Ido,** Department of Gastroenterology and Hepatology, Kagoshima University, Kagoshima City, Kagoshima 890-8520, Japan

**Yoichi Hiasa,** Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City, Ehime 791-0295, Japan

**Kentaro Yoshioka,** Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake City, Aichi 470-1192, Japan

**Hideyuki Nomura,** the Center for Liver Disease, Shin-Kokura Hospital, Kitakyushu City, Fukuoka 803-8505, Japan

**Yoshiyuki Ueno,** Department of Gastroenterology, Yamagata University, Yamagata City, Yamagata 990-9585, Japan

**Masataka Seike,** Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu City, Oita 879-5593, Japan

**Hiromitsu Kumada,** Department of Hepatology, Toranomon Hospital, Kawasaki City, Kanagawa 213-8587, Japan

**Author contributions:** Shakado S and Sakisaka S performed the study design, acquisition, analysis and interpretation of data, literature search, drafting of the manuscript; Chayama K, Okanoue T, Toyoda J, Izumi N, Matsumoto A, Takehara T, Ido A, Hiasa Y, Yoshioka K, Nomura H, Ueno Y, Seike M and Kumada H contributed to the acquisition of data.

**Supported by** A Grant-in-Aid from the Japanese Ministry of Health, Welfare and Labour.

**Institutional review board statement:** The study was not needed to approve by the institutional review board.

**Informed consent statement:** This study is a retrospective report. The additional informed consent from the patients does not apply.

**Conflict-of-interest statement:** Shotaro Sakisaka received Research Fund from MSD;

Kazuaki Chayama received Research Fund from AbbVie, Dainippon Sumitomo, Janssen, Daiichi Sankyo, Roche, MSD, Toray, Otsuka and Tanabe; and Kazuaki Chayama received lecture fees form MSD and Bristol-Myers; Namiki Izumi received lecture fees from Chugai, MSD, Bristol-Myers, Dainippon Sumitomo, Janssen; Tetsuo Takehara received Research Fund from MSD; and Tetsuo Takehara received lecture fees form MSD; Akio Ido received Research Fund from Chugai, MSD, Dai-ichi Sankyo and Tanabe; Kentaro Yoshioka received Research Fund from MSD; and Kentaro Yoshioka had an advisory role to Sanwa Kagaku Kenkyusho; Yoshiyuki Ueno received Research Fund from Tanabe, MSD, Chugai, BMS and Gilead Sciences; Hiromitsu Kumada received lecture fees from MSD K.K, Bristol-Myers Squibb, Janssn Pharmaceutical K.K, Glaxo Smith Kline K.K; and Hiromitsu Kumada had patentroyalties from SRL.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Satoshi Shakado, MD,** **Associate Professor,** Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. shakado@cis.fukuoka-u.ac.jp

**Telephone:** +81-92-8011011

**Fax:** +81-92-8742663

**Received:** May 30, 2015

**Peer-review started:** June 1, 2015

**First decision:** July 6, 2015

**Revised:** August 27, 2015

**Accepted:** November 13, 2015

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To investigate risk factors for development of hepatocellular carcinoma (HCC) in patients with hepatitis C virus-related liver cirrhosis (LC-C).

**METHODS:** To evaluate the relationship between clinical factors including virological response and the development of HCC in patients with LC-C treated with interferon (IFN) and ribavirin, we conducted a multicenter, retrospective study in 14 hospitals in Japan. All patients had compensated LC-C with clinical or histological data available. HCC was diagnosed by the presence of typical hypervascular characteristics on computed tomography and/or magnetic resonance imaging.

**RESULTS:** HCC was diagnosis in 50 (21.6%) of 231 LC-C patients during a median observation period of 3.8 years after IFN and ribavirin therapy. Patients who developed HCC were older (*P* = 0.018) and had higher serum levels of pretreatment alpha-fetoprotein (AFP) (*P* = 0.038). Multivariate analysis revealed the following independent risk factors for HCC development: history of treatment for HCC [*P* < 0.001, odds ratio (OR) = 15.27, 95%CI = 4.98-59.51], AFP levels of ≥ 10 ng/mL (*P* = 0.009, OR = 3.89, 95%CI = 1.38–11.94), and des-γ-carboxy prothrombin (DCP) levels of ≥ 40 mAU/mL at 24 wk after the completion of IFN and ribavirin therapy (*P* < 0.001, OR = 24.43, 95%CI =4.11-138.67).

**CONCLUSION:** We suggested that the elevation of AFP and DCP levels at 24 wk after the completion of IFN and ribavirin therapy were strongly associated with the incidence of HCC irrespective of virological response among Japanese LC-C patients.

**Key words:** Alpha-fetoprotein; Des-gamma-carboxy prothrombin; Interferon; Hepatocellular carcinoma; Hepatitis C virus; Liver cirrhosis; Ribavirin

© **The Author(s) 2015**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Interferon (IFN)-based therapy reduces the rate of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C virus (HCV) infection. However, HCC development has frequently been reported in HCV-related liver cirrhosis (LC-C) patients who achieved sustained virological response. We conducted a multicenter, retrospective study to evaluate the relationship between clinical factors and HCC development in Japanese LC-C patients treated with IFN and ribavirin therapy. We suggested that the elevation of alpha-fetoprotein and des- gamma-carboxy prothrombin levels at 24 wk after the completion of IFN and ribavirin therapy were strongly associated with the incidence of HCC irrespective of virological response among Japanese LC-C patients.

Shakado S, Sakisaka S, Chayama K, Okanoue T, Toyoda J, Izumi N, Matsumoto A, Takehara T, Ido A, Hiasa Y, Yoshioka K, Nomura H, Ueno Y, Seike M, Kumada H. Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development. *World J Hepatol* 2015; In press

**INTRODUCTION**

Chronically hepatitis C virus (HCV) infection is the commonest cause of liver cirrhosis in the world[1]. HCV-related liver cirrhosis (LC-C) patients are the high risk to the development of hepatocellular carcinoma (HCC)[2,3]. Many previous studies suggested that interferon (IFN)-based therapy reduces the rate of HCC development in patients with chronically HCV infection, especially those with sustained virological response (SVR)[4-8]. Non-SVR, male sex, older age, and advanced liver fibrosis have been shown to be risk factors for HCC development in patients treated with IFN[9-13]. Therapy with IFN and ribavirin has been used for LC-C patients, leading to significant effects including SVR. However, the development of HCC has frequently been reported in LC-C patients who achieved SVR[14,15]. The aim of this retrospective, multicenter study was to evaluate the relationship among pre- and post-treatment clinical factors, virological response, and HCC development in Japanese LC-C patients treated with IFN and ribavirin to elucidate the predictive markers for HCC development.

**MATERIALS AND METHODS**

***Patient selection***

We conducted a retrospective, multicenter study in 14 hospitals in Japan. All 290 patients with LC-C were treated with IFN plus ribavirin. A diagnosis of compensated LC-C was defined with the clinical or histological finding. We decided the presence of at least one of the following criteria: liver biopsy demonstrating cirrhosis, multiple nodular appearance of liver surface on peritoneoscopy, liver stiffness greater than 12.5 kPa on transient elastography, presence of esophageal varices, or positive values of cirrhosis criteria[16-18].

Of the 290 patients, 59 developed HCC within 6 mo of completing IFN and ribavirin therapy and were excluded from the study. All analyses used data from the remaining 231 cases. Table 1 shows pretreatment clinical characteristics. Of 231 patients, 189 patients were infected with HCV genotype 1 and 80 patients (34.6%) had received treatment for HCC previously. Eighty patients were treated for HCC with hepatectomy, transcatheter chemoembolization, or radio frequency ablation therapy in each hospital. More detail of treatment history was not investigated in this study. The average follow-up period was 3.8 ± 2.2 years.

***Combination therapy with IFN and ribavirin***

All 231 patients were treated with INF and ribavirin. Pegylated-IFN alpha-2b, pegylated-IFN alpha-2a or IFN alpha-2b were administered to 297 (85.3%), 19(8.2%), 15(6.5%), respectively.

***Surveillance for HCC***

Hepatic ultrasonography, computed tomography (CT), and/or magnetic resonance imaging (MRI) were performed every 3 to 6 mo during follow-up period for HCC surveillance. HCC was diagnosed on the basis of the presence of typical hypervascular characteristics of CT and/or MRI findings.

***Statistical analysis***

We conducted statistical analyze with Fisher’s exact test or Student’s *t*-test. Univariate and multivariate analysis were used with JMP version 9.0 for Macintosh (SAS Institute, Cary, NC). The odds ratio and 95%CI were also calculated.

**RESULTS**

***Pretreatment clinical factors associated with HCC development***

HCC was diagnosed in 50 (21.6%) of 231 LC-C patients treated with IFN and ribavirin during a median follow-up period of 3.8 years (0.6–11.9 years). Patients who developed HCC were older (*P* = 0.018) and had higher serum levels of alpha-fetoprotein (AFP) (*P* = 0.038) than the non-HCC group (Table 1). In our study, no significant difference in HCC development was observed for male sex, platelet count, interleukin 28B genotype, presence of esophageal varices, HCV genotype, type of IFN or IFN treatment history (naive or non-naive).

***Predictive factors associated with HCC development after IFN and ribavirin therapy***

In this study, the duration of treatment with IFN and SVR were not associated with HCC development (Table 2). Serum levels of AFP and des-**γ**-carboxy prothrombin (DCP) were focus to be risk factors for HCC development. Normal range of AFP and DCP were under 10 ng/mL and under 40 mAU/mL, respectively. In patients who developed HCC, serum levels of AFP decreased from 355.1 ng/mL to 42.8 ng/mL during the course of IFN therapy and then increased from 42.8 ng/mL to 63.2 ng/mL at 24 wk after the completion of IFN and ribavirin therapy. In patients who did not develop HCC, serum AFP levels at the beginning, completion, and 24 wk after IFN and ribavirin therapy were 94.1 ng/mL, 15.5 ng/mL, and 11.5 ng/mL, respectively. In patients who did not develop HCC, serum DCP levels at the beginning, completion, and 24 wk after IFN and ribavirin therapy were 328.6 mAU/mL, 25.6 mAU/mL and 18.4 mAU/mL, respectively. As with AFP, serum DCP levels were increased in patients who developed HCC. Serum levels of AFP and DCP were the greatest risk factors for HCC development at 24 wk after the completion of IFN and ribavirin therapy. In patients who did not develop HCC, albumin levels increased from 3.7 g/dL at the completion of IFN and ribavirin therapy to 4.0 g/dL at 24 wk after the completion of treatment. A change of those tumor markers after IFN and ribavirin therapy was shown in Figure 1 and Figure 2.

In our study, SVR was not associated to HCC development. And the levels of AFP and DCP were not associated with HCC development in patients with a SVR (Table 3).

As shown in Table 4, the multivariate analysis revealed the following independent risk factors for HCC development after IFN and ribavirin therapy: history of treatment for HCC (*P* < 0.001, OR = 15.27, 95%CI = 4.98-59.51), AFP levels of ≥ 10 ng/mL at 24 wk after the completion of IFN and ribavirin therapy (*P* = 0.009, OR = 3.89, 95%CI = 1.38-11.94), and DCP levels of ≥ 40 mAU/mL at 24 wk after the completion of IFN and ribavirin therapy (*P* < 0.001, OR = 24.43, 95%CI = 4.11-138.67).

***Cumulative incidence of HCC after IFN and ribavirin therapy***

Patients with a previous history of treatment for HCC had a significantly higher cumulative incidence of HCC development after IFN and ribavirin therapy (*P* < 0.001) (Figure 3). The incidence of HCC was significantly lower in patients with AFP levels of < 10 ng/mL than in those with AFP levels of ≥ 10 ng/mL at 24 wk after the completion of IFN and ribavirin therapy (*P* = 0.004) (Figure 4) as in patients with DCP levels of < 40 mAU/mL than in those with DCP levels of ≥ 40 mAU/mL at 24 wk after the completion of IFN and ribavirin therapy (*P* < 0.001) (Figure 5).

**DISCUSSION**

In this retrospective, multicenter, cooperative study conducted in Japan, we evaluated risk factors of HCC development in LC-C patients treated with IFN and ribavirin. A history of treatment for HCC was a strong risk factor for the development of HCC in our patients. Although HCC has a high recurrence rate, even after curative surgery, a suppressive effect of IFN on HCC recurrence after previous curative treatment has been reported in several studies[19-23]. Furthermore, particularly in Japan, IFN is used as an anti-cancer drug for the treatment of HCC[24-27]. Unfortunately, in LC-C patients treated with IFN and ribavirin, most notably in those with a history of treatment for HCC, IFN therapy did not reduce recurrence rates in our study. Many studies reported that IFN-based therapy not only improves hepatic fibrosis and inflammation but also reduces the incidence of HCC, particularly in patients who achieve SVR[4-13]. In our study, a history of treatment for HCC was a stronger risk factor for HCC development than achieving SVR. In those patients receiving IFN and ribavirin therapy, long-term surveillance for HCC should be conducted even after antiviral therapy with SVR.

In our study, serum levels of AFP decreased after IFN and ribavirin therapy compared to baseline levels in both HCC and non-HCC groups. Serum levels of AFP were further decreased at 24 wk after IFN and ribavirin therapy in the non-HCC group. However, serum levels of AFP were increased at 24 wk after the completion of IFN and ribavirin therapy in patients who developed HCC. Therefore, serum AFP levels at 24 wk after the completion of IFN and ribavirin therapy may be a strong predictor of HCC development in LC-C patients treated with IFN and ribavirin. Serum levels of DCP were also increased at 24 wk after the completion of IFN and ribavirin therapy in patients who developed HCC. Both AFP and DCP serum levels at 24 wk after the completion of IFN and ribavirin therapy were more strongly associated with HCC development than those of pre- and/or post-IFN treatment.

Previous studies reported that a low or decreased AFP level during IFN therapy is associated with a reduced incidence of HCC[28-30]. Serum levels of AFP after IFN-based therapy are also informative, and a higher post-treatment AFP (≥ 6 ng/mL) was a risk factor for HCC development[11,31].

Recently, DCP was demonstrated as a tumor marker for the detection of HCC[32,33]. However, it was unclear whether DCP had value in detecting HCC in patients with LC-C who received IFN and ribavirin therapy. We demonstrated by multivariate analysis that elevated serum levels of AFP (≥ 10 ng/mL) and DCP (≥ 40 mAU/mL) at 24 wk after the completion of IFN and ribavirin therapy were independently associated with HCC development. In clinical practice, even in patients with SVR, careful surveillance for HCC is required in patients with LC-C with an AFP of ≥ 10 ng/mL or a DCP of ≥ 40 mAU/mL at 24 wk after the completion of IFN and ribavirin therapy. A randomized controlled study demonstrated that the LC-C patients who were treated with long-term pegylated-IFN had a low risk of HCC development[34]. Therefore, LC-C patients with an AFP of ≥ 10 ng/mL or a DCP of ≥ 40 mAU/mL at 24 wk after the completion of IFN and ribavirin therapy should be considered for long-term maintenance treatment with pegylated-IFN, irrespective of whether SVR is achieved.

Recently, therapies with direct-acting antivirals without IFN have demonstrated great efficacy against HCV[35-38]. However, it is currently unknown whether serum AFP levels and HCC incidence are decreased in patients treated with IFN-free regimens using direct-acting antivirals.

Although this present study had some limitations, all included patients were diagnosed with well-established cirrhosis without chronic hepatitis. Thus, our findings provide valuable information.

In conclusion, we suggested that elevated serum levels of both AFP and DCP at 24 wk after the completion of IFN and ribavirin therapy are strongly associated with HCC development, irrespective of the virological response, among Japanese LC-C patients. In these patients, additional surveillance for the development of HCC may be required.

**COMMENTS**

***Background***

Chronically hepatitis C virus (HCV) infection is the commonest cause of liver cirrhosis in the world. HCV-related liver cirrhosis (LC-C) patients are the high risk to the development of hepatocellular carcinoma (HCC).

***Research frontiers***

Interferon (IFN)-based therapy reduces the rate of HCC development in patients with chronically HCV infection, especially those with sustained virological response (SVR). However, HCC development has frequently been reported in LC-C patients who achieved SVR. In those patients receiving IFN-based therapy, long-term surveillance for HCC should be conducted even after antiviral therapy with SVR. Knowing risk factors for HCC development is required in aged patients with LC-C treated with anti-viral agents.

***Innovations and breakthroughs***

Previous studies included chronic hepatitis and cirrhosis. In this study, all included patients were diagnosed with well-established cirrhosis. SVR was not associated with HCC development in LC-C patients.

***Applications***

The authors suggested that elevated serum levels of both alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) at 24 wk after the completion of IFN and ribavirin therapy are strongly associated with HCC incidence, irrespective of the virological response, among LC-C patients. In those patients, additional surveillance for the development of HCC may be required.

***Terminology***

Serum levels of both AFP and DCP at 24 wk after the completion of anti-viral agent provide valuable information that can be used to clinical decisions.

***Peer-review***

The authors showed elevated serum levels of both AFP and DCP at 24 wk after the completion of IFN and ribavirin therapy are strongly associated with HCC incidence. This study has a certain clinical impact.

**REFERENCES**

1 **Niederau C**, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D, Nawrocki M, Kruska L, Hensel F, Petry W, Häussinger D. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. *Hepatology* 1998; **28**: 1687-1695 [PMID: 9828236 DOI: 10.1002/hep.510280632]

2 **Hu KQ**, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. *Hepatology* 1999; **29**: 1311-1316 [PMID: 10094980 DOI: 10.1002/hep.510290424]

3 **Sangiovanni A**, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. *Hepatology* 2006; **43**: 1303-1310 [PMID: 16729298 DOI: 10.1002/hep.21176]

4 **Nishiguchi S**, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. *Lancet* 1995; **346**: 1051-1055 [PMID: 7564784 DOI: 10.1016/S0140-6736(95)91739-X]

5 **Yoshida H**, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. *Ann Intern Med* 1999; **131**: 174-181 [PMID: 10428733 DOI: 10.7326/0003-4819-131-3-199908030-00003]

6 **Imai Y**, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. *Ann Intern Med* 1998; **129**: 94-99 [PMID: 9669992 DOI: 10.7326/0003-4819-129-2-199807150-00005]

7 **Serfaty L**, Aumaître H, Chazouillères O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. *Hepatology* 1998; **27**: 1435-1440 [PMID: 9581703 DOI: 10.1002/hep.510270535]

8 **Shiratori Y**, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, Arakawa Y, Hashimoto E, Hirota K, Yoshida H, Ohashi Y, Omata M. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. *Ann Intern Med* 2005; **142**: 105-114 [PMID: 15657158 DOI: 10.7326/0003-4819-142-2-200501180-00009]

9 **Bruno S**, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Larghi A, Cerino A, Podda M, Mondelli MU. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. *Hepatology* 1997; **25**: 754-758 [PMID: 9049231 DOI: 10.1002/hep.510250344]

10 **Cardoso AC**, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, Asselah T, Martinot-Peignoux M, Maylin S, Carvalho-Filho RJ, Valla D, Bedossa P, Marcellin P. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. *J Hepatol* 2010; **52**: 652-657 [PMID: 20346533 DOI: 10.1016/j.jhep.2009.12.028]

11 **Oze T**, Hiramatsu N, Yakushijin T, Miyazaki M, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, Takehara T. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. *Clin Gastroenterol Hepatol* 2014; **12**: 1186-1195 [PMID: 24321207 DOI: 10.1016/j.cgh.2013.11.033]

12 **Hung CH**, Lee CM, Wang JH, Hu TH, Chen CH, Lin CY, Lu SN. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. *Int J Cancer* 2011; **128**: 2344-2352 [PMID: 20669224 DOI: 10.1002/ijc.25585]

13 **Asahina Y**, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. *Hepatology* 2010; **52**: 518-527 [PMID: 20683951]

14 **Ogawa E**, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. *J Hepatol* 2013; **58**: 495-501 [PMID: 23099187 DOI: 10.1016/j.jhep.2012.10.017]

15 **Yamashita N**, Ohho A, Yamasaki A, Kurokawa M, Kotoh K, Kajiwara E. Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes. *J Gastroenterol* 2014; **49**: 1504-1513 [PMID: 24317936 DOI: 10.1007/s00535-013-0921-z]

16 **Ziol M**, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, Marcellin P, Dhumeaux D, Trinchet JC, Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology* 2005; **41**: 48-54 [PMID: 15690481 DOI: 10.1002/hep.20506]

17 **Castéra L**, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* 2005; **128**: 343-350 [PMID: 15685546 DOI: 10.1053/j.gastro.2004.11.018]

18 **Ikeda K**, Saitoh S, Kobayashi M, Suzuki Y, Tsubota A, Suzuki F, Arase Y, Murashima N, Chayama K, Kumada H. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data. *Hepatol Res* 2000; **18**: 252-266 [PMID: 11058829 DOI: 10.1016/S1386-6346(00)00074-7]

19 [**Liver Cancer Study Group of Japan**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Liver%20Cancer%20Study%20Group%20of%20Japan%5BCorporate%20Author%5D). Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. *Ann Surg* 1990; **211**: 277-287 [PMID: 2155591]

20 **Nagasue N**, Uchida M, Makino Y, Takemoto Y, Yamanoi A, Hayashi T, Chang YC, Kohno H, Nakamura T, Yukaya H. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. *Gastroenterology* 1993; **105**: 488-494 [PMID: 8392955]

21 **Miyake Y**, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. *J Viral Hepat* 2010; **17**: 287-292 [PMID: 19732321 DOI: 10.1111/j.1365-2893.2009.01181.x]

22 **Shen YC**, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. *J Hepatol* 2010; **52**: 889-894 [PMID: 20395009 DOI: 10.1016/j.jhep.2009.12.041]

23 **Hsu YC**, Ho HJ, Wu MS, Lin JT, Wu CY. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. *Hepatology* 2013; **58**: 150-157 [PMID: 23389758 DOI: 10.1002/hep.26300]

24 **Sakon M**, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, Kawata S, Imai Y, Iijima S, Monden M. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. *Cancer* 2002; **94**: 435-442 [PMID: 11900229 DOI: 10.1002/cncr.10246]

25 **Uka K**, Aikata H, Takaki S, Miki D, Kawaoka T, Jeong SC, Takahashi S, Toyota N, Ito K, Chayama K. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. *J Gastroenterol* 2007; **42**: 845-853 [PMID: 17940838 DOI: 10.1007/s00535-007-2099-8]

26 **Kasai K**, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. *Cancer* 2012; **118**: 3302-3310 [PMID: 22072099 DOI: 10.1002/cncr.26648]

27 **Shakado S**, Iwata K, Tsuchiya N, Kunimoto H, Yotsumoto K, Fukunaga A, Kuno S, Tanaka T, Sakurai K, Iwashita H, Hirano G, Yokoyama K, Morihara D, Nishizawa S, Takeyama Y, Irie M, Sohda T, Kora S, Yoshimitsu K, Sakisaka S. Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma. *Hepatogastroenterology* 2014; **61**: 557-562 [PMID: 26176035 DOI: 10.5754/hge13950]

28 **Nomura H**, Kashiwagi Y, Hirano R, Tanimoto H, Tsutsumi N, Higashi M, Ishibashi H. Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: A pilot study. *Hepatol Res* 2007; **37**: 490-497 [PMID: 17539990 DOI: 10.1111/j.1872-034X.2007.00073.x]

29 **Chen TM**, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. *J Gastroenterol Hepatol* 2007; **22**: 669-675 [PMID: 17444854 DOI: 10.1111/j.1440-1746.2007.04898.x]

30 **Osaki Y**, Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, Nishikawa H, Saito S, Henmi S, Sakamoto A, Eso Y, Chiba T. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. *J Gastroenterol* 2012; **47**: 444-451 [PMID: 22105231 DOI: 10.1007/s00535-011-0505-8]

31 **Asahina Y**, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. *Hepatology* 2013; **58**: 1253-1262 [PMID: 23564522 DOI: 10.1002/hep.26442]

32 **Ertle JM**, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, Gerken G, Schlaak JF. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma. *Digestion* 2013; **87**: 121-131 [PMID: 23406785 DOI: 10.1159/000346080]

33 **Li C**, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: A systematic review. *Hepatol Res* 2014; **44**: E11-E25 [PMID: 23834468 DOI: 10.1111/hepr.12201]

34 **Lok AS**, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. *Gastroenterology* 2011; **140**: 840-849; quiz e12 [PMID: 21129375 DOI: 10.1053/j.gastro.2010.11.050]

35 **Poordad F**, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. Exploratory study of oral combination antiviral therapy for hepatitis C. *N Engl J Med* 2013; **368**: 45-53 [PMID: 23281975 DOI: 10.1056/NEJMoa1208809]

36 **Kumada H**, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. *Hepatology* 2014; **59**: 2083-2091 [PMID: 24604476 DOI: 10.1002/hep.27113]

37 **Lawitz E**, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. *Lancet* 2014; **383**: 515-523 [PMID: 24209977 DOI: 10.1016/S0140-6736(13)62121-2]

38 **Ferenci P**, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. *N Engl J Med* 2014; **370**: 1983-1992 [PMID: 24795200 DOI: 10.1056/NEJMoa1402338]

**P- Reviewer:** Enomoto H, Kanda T **S- Editor:** Gong XM

**L- Editor:** **E- Editor:**



**Figure 1 A change of the alpha-fetoprotein levels after interferon-based treatment.** AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.



**Figure 2 A change of the des-gamma-carboxy prothrombin levels after interferon-based treatment.** DCP: Des-gamma-carboxy prothrombin; HCC: Hepatocellular carcinoma.



**Figure 3 Cumulative incidence of hepatocellular carcinoma according to the history of treatment for hepatocellular carcinoma.** HCC: Hepatocellular carcinoma.



**Figure 4 Cumulative incidence of hepatocellular carcinoma according to alpha-fetoprotein levels.** 1The value at 24 wk after the completion of interferon-based therapy (ng/mL). AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.



**Figure 5 Cumulative incidence of hepatocellular carcinoma according to des-** **gamma-carboxy prothrombin levels at 24 wk after the completion of interferon-based therapy.** 1The value at 24 wk after the completion of interferon-based therapy (mAU/mL). DCP: Des-gamma-carboxy prothrombin; HCC: Hepatocellular carcinoma.

**Table 1 Pretreatment clinical characteristics of 231 hepatitis C virus-related liver cirrhosis patients treated with interferon and ribavirin**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All patients**  **(*n* = 231)** | **Non HCC**  **(*n* = 181)** | **HCC**  **(*n* = 50)** | ***P-*value1** |
| Sex (M : F) | 111 : 120 | 82 : 99 | 29 : 21 | NS |
| Age (yr) | 60.4 ± 9.2 | 59.6 ± 9.2 | 63.1 ± 9.1 | 0.018 |
| BMI (Kg/m2) | 23.7 ± 3.4 | 23.7 ± 3.5 | 23.9 ± 2.9 | NS |
| Total bilirubin (mg/dL) | 1.1 ± 1.2 | 1.2 ± 1.4 | 0.9 ± 0.3 | NS |
| Albumin (g/dL) | 3.8 ± 0.5 | 3.8 ± 0.5 | 3.8 ± 0.3 | NS |
| Prothrombin (%) | 86.1 ± 15.2 | 86.1 ± 15.8 | 86.1 ± 13.2 | NS |
| ALT (IU/L) | 84.6 ± 64.4 | 86.6 ± 65.8 | 77.1 ± 59.6 | NS |
| GGT (IU/L) | 89.0 ± 124.0 | 89.0 ± 125.2 | 89.3 ± 122.1 | NS |
| Hemoglobin (g/dL) | 13.2 ± 1.8 | 13.1 ± 1.9 | 13.5 ± 1.7 | NS |
| Platelets (104/mm3) | 12.1 ± 6.8 | 12.2 ± 7.2 | 11.7 ± 5.1 | NS |
| AFP (ng/mL) | 94.1 ± 916.1 | 24.2 ± 38.0 | 355.1 ± 1994.9 | 0.038 |
| DCP (mAU/mL) | 261.5 ± 2687.8 | 328.6 ± 3057.3 | 26.5 ± 18.1 | NS |
| IL28B (TT: non TT) | 161：70 | 130：51 | 31 : 19 | NS |
| Presence of EV | 74/191 (38.7%) | 60/146 (41.1%) | 14/45 (31.1%) | NS |
| HCC treatment history | 80 (34.6%) | 44 (24.3%) | 36 (72.0%) | NS |
| HCV Genotype (1/2) | 189：42 | 147：34 | 42：8 | NS |
| IFN treatment  (naive : one more) | 208 (90.0%) | 162 (89.5%) | 46 (92%) | NS |

Data are expressed as number (%) or mean ± standard deviation. All demographic and clinical data are those at the start of antiviral treatment. 1Comparison between non HCC and HCC. HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; NS: Not significant; BMI: Body mass index; ALT: Alanine aminotransferase; GGT: Gamma glutamyl transpeptidase; AFP: Alpha-fetoprotein; DCP: Des-gamma-carboxy prothrombin; IL28B: Interleukin 28B rs8099917; EV: Esophageal varices; IFN: Interferon.

**Table 2 Risk factors for the development of hepatocellular carcinoma in hepatitis C virus-related liver cirrhosis patients treated with interferon and ribavirin**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Non HCC**  **(*n* = 181)** | **HCC**  **(*n* = 50)** | ***P-*value** |
| IFN treatment duration (wk) | 43.1 ± 21.5 | 44.1 ± 22.5 | NS |
| Sustained virological response | 63 (34.8%) | 12 (24%) | NS |
| Albumin levels at the end of IFN treatment (g/dL) | 3.7 ± 0.6 | 3.7 ± 0.6 | NS |
| Prothrombin levels at the end of IFN treatment (%) | 86.0 ± 21.5 | 83.5 ± 11.1 | NS |
| AFP levels at the end of IFN treatment (ng/mL) | 15.5 ± 34.9 | 42.8 ± 96.0 | 0.009 |
| DCP levels at the end of IFN treatment (mAU/mL) | 25.6 ± 47.2 | 255.6 ± 863.2 | 0.017 |
| Albumin levels at 24 wk after IFN treatment (g/dL) | 4.0 ± 0.5 | 3.7 ± 0.5 | 0.004 |
| Prothrombin levels at 24 wk after IFN treatment (%) | 87.8 ± 17.9 | 86.6 ± 14.2 | NS |
| AFP levels at 24 wk after IFN treatment (ng/mL) | 11.5 ± 15.8 | 63.2 ± 193.2 | 0.002 |
| DCP levels at 24 wk after IFN treatment (mAU/mL) | 18.4 ± 12.7 | 354.0 ± 1887.5 | NS |

Data are expressed as number (%) or mean ± standard deviation. HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; IFN: Interferon; NS: Not significant; AFP: Alpha-fetoprotein; DCP: Des-gamma-carboxy prothrombin.

**Table 3 The levels of alpha-fetoprotein and des-gamma-carboxy prothrombin with development of hepatocellular carcinoma in patients with sustained virological response**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Patients with SVR**  ***n* = 75** | **Non HCC**  ***n* = 63** | **HCC**  ***n* = 12** | ***P*-value1** |
| AFP levels at pretreatment (ng/mL) | 16.1 ± 20.2 | 17.8 ± 22.2 | 12.6 ± 14.9 | NS |
| AFP levels at the end of IFN treatment (ng/mL) | 13.7 ± 47.8 | 17.9 ± 57.8 | 5.1 ± 1.8 | NS |
| AFP levels at 24 wk after IFN treatment (ng/mL) | 6.7 ± 10.0 | 5.8 ± 4.1 | 8.0 ± 15.1 | NS |
| Pre DCP levels at pretreatment (mAU/mL) | 93.7 ± 374.1 | 131.3 ± 481.4 | 40.3 ± 69.8 | NS |
| Post DCP levels at the end of IFN treatment (mAU/mL) | 140.0 ± 637.9 | 226.9 ± 864.2 | 42.1 ± 83.3 | NS |
| 24 wk DCP levels at 24 wk after IFN treatment (mAU/mL) | 33.9 ± 52.6 | 28.9 ± 37.4 | 39.3 ± 66.5 | NS |

Data are expressed as number (%) or mean ± standard deviation. 1Comparison between non HCC and HCC. HCC: Hepatocellular carcinoma; AFP: Alpha-fetoprotein; DCP: Des-gamma-carboxy prothrombin; NS: Not significant; SVR: Sustained virological response.

**Table 4 Factors associated with hepatocellular carcinoma development (*n* = 231)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Risk factor** | **Univariate analysis**  ***P*-value** | **Multivariate analysis**  ***P*-value** | **OR** | **95%CI** |
| Age (over 60 yr) | 0.012 | Not significant |  |  |
| HCC treatment history | < 0.001 | < 0.001 | 15.27 | 4.98-59.51 |
| AFP levels at 24 wk after IFN treatment ≥ 10 ng/mL | 0.003 | 0.009 | 3.89 | 1.38-11.94 |
| DCP levels at 24 wk after IFN treatment ≥ 40 mAU/mL | < 0.001 | < 0.001 | 24.43 | 4.11-238.67 |

HCC: Hepatocellular carcinoma; AFP: Alpha-fetoprotein; IFN: Interferon; DCP: Des-gamma-carboxy prothrombin.